CDC panel supports Biotech / Pfizer booster for older and at-risk groups

Newsletter: The road to recovery

The Biden administration’s plan for a comprehensive booster program was given another push because a panel of top public health advisers recommended that the third dose be given only to the elderly and people with underlying health conditions but not those at high-risk jobs exposed to Covid-1 exposure.

The Vaccine Committee recommends that the US Centers for Disease Control and Prevention unanimously vote to recommend a booster dose of the Biotech / Pfizer vaccine for people over the age of 655 and care home residents, and to approve 1-2-2 for people aged 50-4. Medical conditions.

According to the CDC, a group of at least 50 million people with underlying health conditions, the committee voted 6-vot to give a booster to people over the age of 18. However, the panel rejected the third job approval for those working in high-risk jobs who came into contact with Covid in a 9-6 vote.

The Biden administration planned to launch a comprehensive program for all Americans over the age of 16 next week, even before regulators move forward. This angered some scientists, leading to the retirement of two top FDA officials earlier this month.

An FDA advisory panel subsequently refused to approve the Biotech / Pfizer booster for everyone over the age of 16 and instead recommended a more limited group of older and at-risk individuals. The FDA on Wednesday heeded that recommendation, approving a third dose for adults 65 years of age and older and at high risk of severe Covid-1 of or those whose jobs mean they are often exposed to the virus.

After questioning some members, the CDC panel recommended a narrow set of qualifications, whether the need for additional doses exceeded the potential risk of rare heart disease side effects, especially among young people.

Helen Talbot, an associate professor of medicine at Vanderbilt University, said: “Science shows that we really have an effective vaccine and we are not making any decisions about vaccinations.

“I don’t think we have the information to decide on the booster dose for this younger age group,” he added.

The third dose will be available six months after the full dose of vaccination to those who have initially received the Biotech / Pfizer job. Several scientists have questioned its logistics and fairness and expressed frustration over the lack of information on the booster dose of the single shot Johnson & Johnson vaccine.

“I just don’t understand how we can tell people 65 years of age or older‘ you are at serious risk of hospitalization. . . But only half of you can protect yourself now, ”said Sarah Long, a professor of pediatrics at Drexel University College of Medicine.

Scientists have stated that their priority is to get a full vaccination, which is defined two weeks after the second dose of MRNA Jab, made by Biotech / Pfizer and Moderner, or a single J&J shot. The FDA has already approved a third dose of the mRNA vaccine for people with weakened immune systems.

The group has debated how much people need to evaluate their own qualifications, since a booster can be provided based on an individual’s word – which has allowed some people to snatch the booster before the government recommends it.

“If you don’t give them flexibility, you’re going to deprive these patients of something that could save their lives,” said Sandra Frihofer, a representative of the American Medical Association.

Some members questioned the amount of data available. Camille Cotton, an infectious disease specialist at Massachusetts General Hospital, said the number of black and Latino people under the age of 655 is high and more information is needed for racial reflection. “It’s not the same result in all ethnic groups,” he said.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button